AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results